Tag Archives: World Health Assembly

Will WHO Member States Pony Up for Neglected Diseases?

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. […]
Posted in Emerging Markets, Global, IP, leadership, Legal, Manufacturing, Market Access, pricing, R&D | Also tagged , , , , , , , , , | Leave a comment

WHO Threatens Industry Shut-out on Counterfeit Regulation

Big Pharma believes that a global generics franchise might give it a softer landing off the patent cliff, but governments that sponsor and regulate the industry are still acting a bit slow on the uptake. The reason? Anti-IP activists are again poisoning the well on global access to medicines, engaging the bigger emerging market governments […]
Posted in Global | Also tagged , , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts […]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta